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Introduction
Nicotinamide adenine dinucleotide (NAD + ) is an essential redox molecule and a key player in several signaling pathways that govern fundamental biological processes (Berger et al., 2004; Canto et al., 2015) . Redox reactions involve the transfer of reducing equivalents between the oxidized (NAD + ) and reduced (NADH) forms of the nucleotide. Although, this electron carrier function is critical for catabolic reactions and energy production, it does not cause any net loss of NAD + . On the other hand, the signaling processes in which NAD + is used as a co-substrate in multiple enzymatic reactions lead to its degradation. Three distinct families of enzymes use NAD + as cosubstrate: poly(ADP-ribose) polymerases (PARPs), ADP-ribosyl cyclases (e.g. CD38) and sirtuins (Pehar et al., 2018) .
Sirtuins (Sir2-like enzymes) are NAD + -dependent deacylases that play a key role in transcription, DNA repair, metabolism, and oxidative stress resistance (Imai and Guarente, 2014) . Modulating NAD + availability appears to regulate endogenous sirtuin activity and has been shown to be a potential therapeutic approach for age-related diseases ( In order to maintain viability, cells have to continuously synthesize NAD + . NAD + neosynthesis can occur from L-tryptophan (kynurenine pathway), nicotinic acid (Priess-Handler pathway) or nicotinamide riboside (NR) (Belenky et al., 2007a; Bieganowski and Brenner, 2004; Ruddick et al., 2006) . However, since all the major NAD +consuming enzymes generate nicotinamide (NAM) as a byproduct, eukaryotic cells have evolved a rescue pathway capable of re-synthesizing NAD + from NAM. The enzyme nicotinamide phosphoribosyltransferase (NAMPT) catalyzes the conversion of NAM and 5'-phosphoribosyl-1-pyrophosphate to nicotinamide mononucleotide (NMN).
Amyotrophic lateral sclerosis (ALS) is characterized by the progressive degeneration of motor neurons in the spinal cord, brain stem, and motor cortex. Motor neuron death leads to muscle weakness and paralysis. Typically, death occurs due to respiratory paralysis in three to five years from the time of symptoms onset (Brown and Al-Chalabi, 2017) . Approximately 5-10% of the ALS cases have a familial history of the disease (familial ALS, FALS) and are most frequently linked to a dominant mutation.
The rest of the cases do not have a familial history (sporadic ALS, SALS) and may result from a yet unidentified environmental exposure or genetic mutations (Renton et al., 2014) . The first ALS-linked gene identified was superoxide dismutase 1 (SOD1) (Rosen et al., 1993) . Mutations in SOD1 account for up to 20% of FALS and 1 -2% of apparently SALS cases. Mutations in several other genes, like TAR DNA binding protein (TARDBP) and fused in sarcoma (FUS) can also be found in FALS and SALS cases, while a repeat expansion in C9orf72 (chromosome 9, open reading frame 72) is the most common genetic cause of ALS (Brown and Al-Chalabi, 2017; Ravits et al., 2013; Renton et al., 2014) . In the sera of patients with ALS, significant alterations in the level of key molecules of the tryptophan-nicotinamide metabolic pathway (e.g. circulating nicotinamide) have been reported. This observation may originate from impaired microbiome-derived nicotinamide metabolism in patients with ALS. Accordingly, nicotinamide supplementation appears to be protective in an ALS (hSOD1 G93A ) mouse model (Blacher et al., 2019) .
Astrocytes play a key role determining motor neuron fate in ALS models, and primary astrocytes over-expressing mutant hSOD1 or mutant hFUS induce motor neuron death in co-culture (Kia et al., 2018; Nagai et al., 2007; Vargas et al., 2006) . In line with these observations, astrocytes differentiated from human postmortem ALS spinal cord-derived progenitor cells and astrocytes obtained from the transdifferentiation of fibroblasts from FALS and SALS patients are also toxic for motor neurons in co-culture (Haidet-Phillips et al., 2011; Meyer et al., 2014) .
Notably, therapeutic strategies aimed at reverting astrocyte-mediated toxicity increase motor neuron survival and improve motor performance in ALS mouse models (de Boer et al., 2014; Miquel et al., 2014; Song et al., 2016; Vargas et al., 2008) .
Treatment with NAD + precursors enhance NAD + availability in mutant hSOD1-J o u r n a l P r e -p r o o f Journal Pre-proof expressing astrocytes, leading to increased resistance to oxidative stress and the reversal of their toxicity toward co-cultured motor neurons (Harlan et al., 2019; Harlan et al., 2016) . Here we sought to determine the effect of enhancing NAD + availability in the ALS-like pathology developed by hSOD1 G93A mice. Our results show that NR supplementation delays motor neuron degeneration, decreases markers of neuroinflammation in the spinal cord, appears to modify muscle metabolism and extends the survival of hSOD1 G93A mice. In addition, we present evidence of altered expression of SIRT6 and NAD + synthesizing enzymes in ALS patients, which can be directly relevant to the pathophysiology of the disease. Since NR appears to be orally bioavailable and safe in humans (Trammell et al., 2016) , our data suggests this would be the preferred therapeutic strategy to enhance NAD + levels in ALS.
Materials and methods
Reagents-All chemicals and reagents were from Sigma-Aldrich unless otherwise specified. Primers were obtained from Integrated DNA Technologies (see supplemental   table 1) .
Animals-B6.Cg-Tg(SOD1*G93A)1Gur/J mice (Gurney et al., 1994) were obtained from The Jackson Laboratory and maintained in hemizygosis in a C57BL/6J background. Littermates were randomly assigned to a control diet (Teklad 2016S) or a test diet containing NR 2.4g/kg (2016S Teklad + NR). Ad libitum feeding of this modified diet translates in approximately 400 mg/kg/day of NR in adult mice (Zhang et al., 2016) . hSOD1H 46R/H48Q mice were provided by Dr. David Borchelt [35] and have been backcrossed into C57BL/6J pure background for more than 10 generations. C57BL/6J.129 CD38−/− mice have been previously described (Partida-Sanchez et al., 2001) . In order to generate the animals for this study, hemizygous hSOD1 G93A males were mated with CD38(-/-) females to obtain breeders with the following genotype CD38(+/-)/hSOD1 G93A (+/-) and CD38(+/-)/hSOD1 G93A (-/-). Then, CD38(+/-placed on its side. Mice that were unable to right themselves within 20 seconds were euthanized and recorded as dead. Mice were weighed two times per week and disease onset was retrospectively determined as the time when mice reached peak body weight.
Hind-limb grip strength was determined using a grip strength meter (San Diego Instruments). Tests were performed by allowing the animal to grasp the grid with both hind-limbs and pulling the animal straight away from the grid until it released the platform. Grip strength was measured once a week, in each session the average peak force of three attempts was recorded. For the animals in the life-span study, relative quantitative PCR was used to estimate hSOD1 gene copy number. One of the male breeders that fathered the litters used in these studies was used as a reference for copy number estimation. Animals with less relative gene copy number that the reference breeder were not used in the study. All animal procedures were carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Immunofluorescence and histochemistry-Antigen retrieval and staining in paraffin embedded tissues was performed as previously described (Vargas et al., 2008) .
Mice lumbar spinal cord sections were stained with anti-GFAP (Novus, NBP2-29415, Lot 2670-1P180807) and anti-IBA1 (Fujifilm Wako, 013-27691, Lot PTJ0731) antibodies.
Nuclei were counterstained with DAPI (4(,6-Diamidino-2-phenylindole dihydrochloride).
Several sections (the number is indicated in the corresponding figure legend) from 4 animals in each group were stained and imaged concurrently. Immunofluorescent Real-time PCR and western blot analysis-RNA extraction, RNA retrotranscription, real-time PCR and western blot analysis were performed as previously described (Pehar et al., 2014; Vargas et al., 2008) .
Statistical analysis-Survival and onset data was analyzed with Kaplan-Meier curves and log rank test. Groups of at least 4 animals were used for biochemical analysis and all data are reported as mean ± SD. Comparisons between two groups were performed with an unpaired t-test. Multiple group comparisons were performed with two-way ANOVA with Tukey's post-test and differences were declared statistically significant if p ≤ 0.05. All statistical computations were performed using GraphPad Prism 6.0 (GraphPad Software).
Results
To determine the effect of increasing NAD + availability in ALS mouse models we used two strategies. A transgenic approach, ablation of a NAD + consuming enzyme (CD38), and a dietary supplementation approach with nicotinamide riboside (NR, a bioavailable NAD + intermediate). Originally described as an ectoenzyme, CD38 is also present in the endoplasmic reticulum, and in the nuclear and mitochondrial membrane (Aksoy et al., 2006) . Knockout of CD38 results in a significant increase in the steady background. We observed that the ablation of CD38 does not modify the survival of the two hSOD1-linked ALS mouse models used ( Figure 1 ).
NR is orally bioavailable in animals and humans (Airhart et al., 2017; Dellinger et al., 2017; Trammell et al., 2016; Zhang et al., 2016) . NR treatment increases intracellular NAD + concentration and enhances NAD + -dependent sirtuin activity in different culture and animal models (Belenky et al., 2007b; Harlan et al., 2016; Zhang et al., 2016) . Ad libitum feeding of a NR supplemented diet, that translates in approximately 400 mg/kg/day of NR in adult mice, modestly extended the survival of hSOD1 G93A mice ( Figure 2 ). Although mice in control and NR diet had similar median onset (Figure 2A , C), NR appeared to slow down disease progression as reflected by a significant delay in the age at which mice displayed 10% and 15% body weight loss (as percentage of peak body weight) ( Figure 2D , E). The NR diet also improved hindlimb grip strength around the age of symptoms onset ( Figure 2F ). In addition, NR supplementation decreased glial activation in the spinal cord of early symptomatic mice, as determined by immunofluorescence against astrocyte (Gfap) and microglia (Iba-1) markers ( Figure 3A-C) . The neuroprotective effect conferred by NR is evidenced by a delay in the loss of large motor neurons in the lumbar spinal cord of hSOD1 G93A mice on the experimental diet (an average of about 11% more motor neurons was observed in the NR diet group, Figure 3D) . Moreover, we observed a significant decrease in the expression of several inflammatory markers highly expressed by glial cells in the CNS ( Figure 3E -H). Because we have shown that the NAD + -dependent enzymes, SIRT3 and SIRT6 are important regulators of motor neuron survival in in vitro models of ALS, we analyzed the expression levels of Sirt3 and Sirt6 in these experimental animals (Harlan et al., 2019; Harlan et al., 2016) . Although NR supplementation has no effect on their expression level, we found that the mRNA levels Figure 6 ). The increase in NAMPT mRNA data observed in ALS patients is in line with an overall increase in NAMPT protein expression previously described in these patients (Wang et al., 2017) . Quantitative protein and immunohistochemistry analysis confirmed a decrease in NMNAT2 expression in the spinal cord of ALS patients , which appears particularly evident in motor neurons (Figure 6 G, H, I) . Changes in Nmnat1 and Nmnat2 mRNA expression are also evident in the spinal cord early symptomatic hSOD1 G93A mice but not in young asymptomatic mice (Supplemental Figure 1) , further suggesting that these changes may be linked to the neurodegenerative process observed in ALS.
Discussion
Enhancing NAD + availability has been shown to confer protection in animals models of Alzheimer's disease (Gong et al., 2013; Hou et al., 2018; Sorrentino et al., 2017) and in in vitro models of ALS (Harlan et al., 2019; Harlan et al., 2016) . Here we showed that a diet supplemented with NR modestly increases the survival of Our data confirms an earlier observation made in a smaller cohort of ALS patients that showed no change in SIRT3 mRNA expression (Korner et al., 2013) . The discrepancy between the data on Sirt3 expression in the spinal cord of symptomatic hSOD1 G93A mice and the data obtained in ALS patients highlights the need for additional studies to fully characterize the role of this sirtuin during motor neuron degeneration. On the other hand, we present for the first-time evidence of a significant downregulation of SIRT6 expression in the spinal cord of ALS patients ( Figure 5 ). Since, SIRT6 can be neuroprotective, this observation lends further support to the rational of enhancing NAD + availability to increase sirtuin activity in ALS. In this respect, it is worth J o u r n a l P r e -p r o o f Journal Pre-proof noting that enhancing NAD + availability will not necessarily increase the expression of the target enzyme but its activity.
Treatment with NAD + precursors, like NR, reverses mitochondrial dysfunction and metabolic changes associated with aging and high-fat diet intake (Canto et al., 2012; Mills et al., 2016; Mouchiroud et al., 2013; Yoshino et al., 2011; Zhang et al., 2016) .
Moreover, NR supplementation has been shown to increase skeletal muscle NAD + metabolome in aged human control subjects (Elhassan et al., 2019) . Metabolic changes in affected muscles are one of the earlier changes observed in ALS animal models (Gonzalez de Aguilar et al., 2008; Palamiuc et al., 2015; Palma et al., 2016) , and strategies aimed at overcoming metabolic constraints have been shown to be protective in these models (Dupuis et al., 2004; Manzo et al., 2019) . Pfkfb3 controls both the synthesis and degradation of fructose-2,6-bisphosphate (F2,6BP), a regulatory molecule that controls glycolysis in eukaryotes (Bolanos et al., 2010) . F2,6BP activates glycolysis through allosteric modulation of phosphofructokinase (Pfkm). Cpt1b is the rate-limiting enzyme in the utilization of long-chain fatty acids for beta-oxidation in muscle mitochondria (Lundsgaard et al., 2018) . The expression of both enzymes is significantly downregulated in the gastrocnemius muscle of symptomatic hSOD1 G93A mice (Figure 4 ) and NR partially restores Pfkfb3 and Cpt1b expression, suggesting that the experimental diet may improve metabolic flexibility in the affected skeletal muscle.
Sirt3 regulates metabolic pathways in fuel-producing and fuel-utilizing tissues (Dittenhafer-Reed et al., 2015) . Similar to the finding in the spinal cord, Sirt3 expression is significantly downregulated in the gastrocnemius muscle of symptomatic hSOD1 G93A mice in the control diet, while Sirt3 levels remain unchanged in mice fed the NRsupplemented diet. The changes in gene expression observed in the hSOD1 G93A mice on the NR supplemented diet can be due to a direct effect of NR reprograming the metabolism of the skeletal muscle or could be an indirect effect due to a delay in changes associated with muscle denervation and wasting (e.g. decrease in the expression of these enzymes as muscle wasting ensues).
A previous manuscript argued for a dysregulation of the amount of intracellular and extracellular levels of NAMPT in the spinal cord of ALS patients (Wang et al., 2017) but showed an overall increase in NAMPT expression. Our data confirms that there is a Figure 6C, Supplemental Figure 2) . Similarly, Nmnat2 mRNA is significantly down-regulated in both the lumbar spinal cord and gastrocnemius muscle of early symptomatic hSOD1 G93A mice (Supplemental Figure 1B, C) . Of the three NMNAT isoforms, NMNAT2 has been shown to be an essential survival factor for maintenance of healthy axons (Conforti et al., 2014; Gerdts et al., 2016) , and reduction of NMNAT2 expression below a threshold level triggers degeneration even in uninjured axons (Gilley et al., 2019) . Moreover, NMNAT2 expression levels directly correlate with cognitive performance, and a decrease in NMNAT2 expression is observed in Alzheimer's disease patients (Ali et al., 2016) . NMNAT2 acts as a NAD + -synthesizing enzyme as well as a chaperone for protein refolding (Ali et al., 2016; Zhai et al., 2008) .
Hypomorphic human NMNAT2 variants cause skeletal muscle hypoplasia and fetal akinesia apparently due to defects in both NAD + synthesis and chaperone functions (Lukacs et al., 2019) . NMNAT2 overexpression provides neuroprotection in several models of neurodegeneration (Ali et al., 2013; Conforti et al., 2014) , and consistent with its rate-limiting role in NAD + synthesis, NAMPT overexpression is also protective in several models of neurodegeneration (Harlan et al., 2016; Jing et al., 2014; Pehar et al., 2018; Wang et al., 2016) . Thus, the observed NAMPT upregulation in ALS patients could be a compensatory mechanism in response to a decrease in NMNAT2 expression. (Herskovits et al., 2018; Watanabe et al., 2014) . However, the apparent safety and simplicity of NAD + boosting strategies (Airhart et al., 2017; de la Rubia et al., 2019; Dellinger et al., 2017; Trammell et al., 2016) justifies future efforts to improve NAD + precursor delivery strategies to target certain tissues or cell types in order to achieve greater efficacy. In addition, we present evidence of altered expression of SIRT6 and NAD + synthesizing enzymes in ALS patients, which can be directly relevant to the pathophysiology of disease. Taken together, our results indicate that enhancing NAD + availability could be a potential therapeutic strategy for ALS.
Conclusions
Enhancing NAD + availability is being considered as a possible treatment for multiple diseases. The decrease in the expression of NMNAT2 and SIRT6 observed in the spinal cord of ALS patients suggest that normal NAD + metabolism, as well as, the activity of this neuroprotective sirtuin may be compromised in these patients. This provides further support to the use of therapeutic approaches that increase NAD + availability and/or potentiate sirtuin activity in ALS. Our data demonstrates that the strategy used to enhance NAD + levels defines the biological outcome in ALS models. The results presented here support the use of NAD + bioavailable precursors as the preferred strategy to enhance NAD + levels in ALS.
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Science 352, 1436-1443. hSOD1 G93A mice on control or NR-supplemented diet exhibited 10% weight loss (age at 90% of peak body weight, mean ± SD). E) Age at which hSOD1 G93A mice on control or NR-supplemented diet exhibited 15% weight loss (age at 85% of peak body weight, mean ± SD). F) Ratio of hind-limb grip strength to body weight at 110 days of age in hSOD1 G93A mice on control or NR-supplemented diet (mean ± SD). The number and sex of the animals for panels (D), (E) and (F) are the same as in (C). The approach used to enhance NAD + levels defines the biological outcome in ALS models.
Figure legends
Nicotinamide riboside delays motor neuron degeneration in hSOD1 G93A -ALS mice.
CD38 ablation does not confer protection in hSOD1 G93A -ALS mice.
The expression of NMNAT2 and SIRT6 decreases in the spinal cord of ALS patients. 
